Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Megan Durham
Investigational New Drugs
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
Journal of Clinical Oncology
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study
Nature
In situ tumour arrays reveal early environmental control of cancer immunity
Therapeutics Advances in Medical Oncology
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
Journal of Patient-Reported Outcomes
Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)
Lung Cancer
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
Investigational New Drugs
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
Current Treatment Options in Oncology
Novel Estrogen Receptor-Targeted Agents for Breast Cancer
Clinical Cancer Research
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)